Olanzapine treatment for patients with schizophrenia and substance abuse.
about
Bipolar disorder and alcohol use disorder: a reviewMetabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the MythsSubstance abuse and schizophrenia: pharmacotherapeutic interventionRevisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behaviorWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.Potential benefits of quetiapine in the treatment of substance dependence disordersEvolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.Clinical aspects of substance abuse in persons with schizophrenia.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.Olanzapine: a 5-year perspective.Hope and schizophrenia: an integrative review.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use DisordersNon-medical use of olanzapine by people on methadone treatment.Treating comorbid substance use disorders in schizophrenia.Antipsychotic treatment of adolescent dual diagnosis patientsAntipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review.Pharmacological treatment of schizophrenia with comorbid substance use disorder.Improved Sleep, Diet, and Exercise in Adults with Serious Mental Illness: Results from a Pilot Self-Management Intervention.Treatment of substance use disorders in schizophrenia.Atypical antipsychotics: revolutionary or incremental advance?Quetiapine mitigates the ethanol-induced oxidative stress in brain tissue, but not in the liver, of the ratRelationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics.Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?Abuse of olanzapine by substance abusers.Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.
P2860
Q22252584-D251E353-BA49-437B-A685-B5D0ECC886A7Q24596954-BC76806C-78F8-4038-8F9F-DC1E107DEA56Q24621711-8350BD07-7B9F-4897-B09F-DA16E64F3A18Q26801102-326DEBF4-8115-4716-90CD-D23F3E8E5B08Q33223628-83D44B5F-85B0-45C2-9A5D-DF73478F711CQ34554089-C2274E8E-044C-4903-92A9-379663A2C205Q34994773-84E5A1B0-CA4A-417A-9C4E-248EC6810FF2Q35084956-B3E78603-2998-4219-8BF5-9720DC57633CQ36059843-1FEF0E3A-0576-4AE5-BB77-FA4934CD59A8Q36083997-09E8B6C9-F90C-43AD-83AA-125D75C5DB19Q36267882-6CA5EE47-90A6-4802-8DAC-212FFEF10EBCQ36511290-35A06B07-E5F4-4A9E-9ADB-E2C827935D7CQ36646191-2994FD23-9B15-45C0-BC34-FFA74CAD71EEQ36927085-17CA8C0E-0FC3-4BAF-9CF5-C5A7C2D8D815Q37704418-35801F44-D74B-42EE-A0EF-13229BFBEECDQ37760932-277A8F41-BB04-4124-9B70-83346362846DQ38024348-0AFD95D7-1D8C-4977-BF25-75BA9EB957EBQ38618558-4D49B322-9E04-4E23-A05A-68540D7B02AFQ38658672-4A3C4D36-34A8-4F70-98E3-AB7A8FF4D103Q38813414-4914C8EB-3842-4588-BCE4-421B0F7F8927Q38813826-A008CED5-9CF0-495A-B9BE-EEBB07243E84Q39412178-96CFFBF4-6C5A-414A-8BA5-FA918D805C08Q42091436-ADB0C7A2-2FF2-446D-A044-E5E64B17F95AQ44596380-F04A36EB-7FD4-403C-AF02-933174D9DD43Q45929001-FA66F98D-101B-4FA2-9101-C11F6B04BB04Q46832986-E7DF914D-7E19-4995-826A-49D86D5D4020Q51937580-3D6C63C5-1266-4892-B8F5-3BD0E28D8A5C
P2860
Olanzapine treatment for patients with schizophrenia and substance abuse.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Olanzapine treatment for patients with schizophrenia and substance abuse.
@en
Olanzapine treatment for patients with schizophrenia and substance abuse.
@nl
type
label
Olanzapine treatment for patients with schizophrenia and substance abuse.
@en
Olanzapine treatment for patients with schizophrenia and substance abuse.
@nl
prefLabel
Olanzapine treatment for patients with schizophrenia and substance abuse.
@en
Olanzapine treatment for patients with schizophrenia and substance abuse.
@nl
P2093
P1476
Olanzapine treatment for patients with schizophrenia and substance abuse.
@en
P2093
C D Peabody
C G Johnson
K H Littrell
N M Hilligoss
P304
P356
10.1016/S0740-5472(01)00205-7
P577
2001-12-01T00:00:00Z